Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension

Mise à jour : Il y a 4 ans
Référence : NCT01223352

Femme et Homme

Extrait

The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial hypertension (PAH) <12 years of age.


Critère d'inclusion

  • pulmonary arterial hypertension


Liens